Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin DDI with Digoxin in Healthy Subjects
NCT03197324Phase 1Completed
- Sponsor
- Theracos, Inc.
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Theracos, Inc. Primary endpoints: Digoxin Maximum Observed Plasma Concentration up to 120 hours, Digoxin Time of Maximum Observed Plasma Concentration up to 120 hours and 2 more. Started Jul 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03197324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197324.